| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
The primary target of Sofosbuvir impurity M, as an impurity of Sofosbuvir, is the HCV NS5B polymerase, an enzyme essential for hepatitis C virus RNA replication. Sofosbuvir acts as a nucleotide analog inhibitor that terminates viral RNA chain elongation. As a diastereoisomer of Sofosbuvir, Sofosbuvir impurity M is a structural variant that serves as a reference standard for analytical purposes rather than a therapeutic agent. Its presence in Sofosbuvir batches is monitored to ensure the quality and purity of the active pharmaceutical ingredient. The compound provides insight into how structural deviations affect antiviral activity.
|
|---|---|
| ln Vitro |
In vitro studies of Sofosbuvir impurity M are primarily focused on its use as an analytical reference standard rather than its biological activity. As a diastereoisomer of Sofosbuvir, which is a potent HCV NS5B polymerase inhibitor, the impurity may have different biological activity compared to the parent compound. The compound is used in analytical method development and quality control to ensure the purity and potency of Sofosbuvir drug products. Its presence and concentration are monitored using HPLC or other analytical techniques. Sofosbuvir impurity M provides insight into how structural deviations affect activity.
|
| ln Vivo |
In vivo studies of Sofosbuvir impurity M are not typically performed, as it is used as an analytical reference standard rather than a therapeutic agent. As an impurity and diastereoisomer of Sofosbuvir, it is not intended for administration to animals or humans. The compound's primary application is in quality control and analytical method development for the antiviral drug Sofosbuvir. Its presence in Sofosbuvir batches is regulated to ensure the safety and efficacy of the drug product. The compound provides insight into how structural deviations affect activity.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, Sofosbuvir impurity M is not typically used in biological activity assays, as it is primarily an analytical reference standard. However, the compound could be evaluated in HCV NS5B polymerase assays to compare its activity with that of Sofosbuvir. These assays involve incubating the compound with recombinant NS5B polymerase, RNA template, and nucleotides. Polymerase activity is quantified by measuring RNA synthesis. IC₅0 values can be determined from dose-response curves. The compound's ability to inhibit HCV replication can also be assessed in cell-based HCV replicon assays. Such studies would provide insight into how structural deviations affect activity.
|
| Cell Assay |
For in vitro cellular experiments, Sofosbuvir impurity M is not typically used in cell-based assays, as it is primarily an analytical reference standard. However, the compound could be tested in HCV replicon cell lines to evaluate its antiviral activity compared to Sofosbuvir. Cells are cultured in appropriate media and treated with various concentrations of the compound. HCV RNA replication is measured by qPCR or other detection methods. Cell viability is monitored to assess cytotoxicity. Such studies would provide insight into how structural deviations affect antiviral activity and help understand the structure-activity relationships of Sofosbuvir analogs.
|
| Animal Protocol |
For in vivo animal experiments, Sofosbuvir impurity M is not typically administered to animals, as it is used as an analytical reference standard rather than a therapeutic agent. However, the compound could be studied in animal models to evaluate its pharmacokinetic properties and potential toxicity if it were to be present as an impurity in Sofosbuvir formulations. Such studies would help understand the safety profile of Sofosbuvir impurities. The compound provides insight into how structural deviations affect activity. Animal studies would follow appropriate ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sofosbuvir impurity M are not characterized, as it is used as an analytical reference standard rather than a therapeutic agent. As a diastereoisomer of Sofosbuvir, its pharmacokinetic properties would likely be similar to those of Sofosbuvir, but differences due to stereochemistry could affect its absorption, distribution, metabolism, and excretion. Sofosbuvir is a nucleotide analog prodrug with good oral bioavailability. The compound provides insight into how structural deviations affect activity. Further pharmacokinetic studies would be needed to fully characterize its profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Sofosbuvir impurity M are limited, as it is used as an analytical reference standard rather than a therapeutic agent. As an impurity of Sofosbuvir, its toxicity would be relevant for the safety of Sofosbuvir drug products. Impurities in pharmaceutical products are regulated to ensure they are present at safe levels. The compound provides insight into how structural deviations affect activity. Standard toxicological assessments would include cytotoxicity screening in relevant cell lines and genotoxicity testing. As with all research chemicals, appropriate safety precautions should be taken when handling Sofosbuvir impurity M.
|
| Additional Infomation |
Sofosbuvir impurity M is a research compound used as an analytical reference standard for Sofosbuvir quality control. No clinical trials or regulatory approvals have been reported for this specific impurity as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a diastereoisomer and impurity of Sofosbuvir, an HCV NS5B polymerase inhibitor and blockbuster drug approved for chronic hepatitis C. It provides insight into how structural deviations affect activity and is used in analog structure-activity studies.
|
| Molecular Formula |
C22H30N3O10P
|
|---|---|
| Molecular Weight |
527.461467266083
|
| Exact Mass |
527.166
|
| CAS # |
2095551-10-1
|
| PubChem CID |
130337055
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
36
|
| Complexity |
909
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O=[P@@](N[C@@H](C)C(OC(C)C)=O)(OC[C@@H]1[C@@H](O)[C@@](O)(C)[C@H](N2C=CC(NC2=O)=O)O1)OC3=CC=CC=C3
|
| InChi Key |
WAKQLZVLNOKKHE-YMGVOGLASA-N
|
| InChi Code |
InChI=1S/C22H30N3O10P/c1-13(2)33-19(28)14(3)24-36(31,35-15-8-6-5-7-9-15)32-12-16-18(27)22(4,30)20(34-16)25-11-10-17(26)23-21(25)29/h5-11,13-14,16,18,20,27,30H,12H2,1-4H3,(H,24,31)(H,23,26,29)/t14-,16+,18+,20+,22-,36?/m0/s1
|
| Chemical Name |
propan-2-yl (2S)-2-[[[(2R,3R,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8959 mL | 9.4794 mL | 18.9588 mL | |
| 5 mM | 0.3792 mL | 1.8959 mL | 3.7918 mL | |
| 10 mM | 0.1896 mL | 0.9479 mL | 1.8959 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
